Prevalence of bla OXA-48 and other carbapenemase encoding genes among carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Egypt.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Pseudomonas aeruginosa*/genetics ; Pseudomonas aeruginosa*/drug effects ; Pseudomonas aeruginosa*/enzymology ; Pseudomonas aeruginosa*/isolation & purification ; beta-Lactamases*/genetics ; Carbapenems*/pharmacology ; Pseudomonas Infections*/microbiology ; Pseudomonas Infections*/epidemiology ; Bacterial Proteins*/genetics ; Integrons*/genetics ; Anti-Bacterial Agents*/pharmacology ; Microbial Sensitivity Tests*; Humans ; Egypt/epidemiology ; Prevalence
    • Abstract:
      Background: Resistance to carbapenem, the last line of treatment for gram-negative bacterial infections has been increasing globally and becoming a public health threat. Since integrons may aid in the transmission of resistance genes, the purpose of this study was to detect the frequency of class 1, 2, and 3 integrons as well as carbapenem-resistant genes in clinical isolates of P. aeruginosa that are resistant to carbapenem.
      Methods: This study was carried out on 97 clinical isolates of P. aeruginosa isolated from wound and urine samples. The antimicrobial susceptibility for all isolates was tested by the disc diffusion method. The presence of integrons and carbapenem-resistant genes among carbapenem-resistant P. aeruginosa isolates was evaluated by conventional PCR.
      Results: The antimicrobial resistance rate among P. aeruginosa clinical isolates was high, with imipenem resistance in 58.8% of the studied isolates. In this study, 86% of the carbapenem-resistant P. aeruginosa isolates carry carbapenemase genes, with bla VIM being the most common gene followed by the bla OXA-48 gene. Class 1 and class 2 integrons were reported in 37 (64.9%) and 10 (17.5%) of the tested carbapenem-resistant P. aeruginosa isolates, respectively.
      Conclusion: Our data reported a high prevalence of class 1 integrons in carbapenem-resistant P. aeruginosa clinical isolates, suggesting the important role of integrons in carbapenem-resistant gene transfer among such isolates.
      Competing Interests: Declarations Ethics approval and consent to participate The study was approved by the research ethical committee of the Faculty of Medicine, Minia University (approval number, 1144/04/2023). The work has been carried out under the code of ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans. Written informed consent was obtained from all participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Declarations of interests The authors declare that they have no competing interests.
      (© 2024. The Author(s).)
    • References:
      J Glob Antimicrob Resist. 2021 Sep;26:285-291. (PMID: 34284128)
      Open Microbiol J. 2016 Nov 30;10:188-196. (PMID: 28077975)
      Expert Rev Anti Infect Ther. 2017 Mar;15(3):277-297. (PMID: 27915487)
      Germs. 2018 Mar 03;8(1):31-40. (PMID: 29564246)
      Clin Microbiol Infect. 2011 Aug;17(8):1272-5. (PMID: 21375657)
      J Clin Microbiol. 2009 Jan;47(1):230-4. (PMID: 19020065)
      J Microbiol Immunol Infect. 2021 Aug;54(4):665-672. (PMID: 32362456)
      Indian J Med Microbiol. 2016 Apr-Jun;34(2):252-3. (PMID: 27080790)
      Ann Clin Microbiol Antimicrob. 2015 Oct 20;14:45. (PMID: 26487554)
      Infect Drug Resist. 2019 Nov 07;12:3455-3461. (PMID: 31819540)
      Prim Care. 2018 Sep;45(3):467-484. (PMID: 30115335)
      Antibiotics (Basel). 2022 May 20;11(5):. (PMID: 35625338)
      FEMS Immunol Med Microbiol. 2005 Jun 1;44(3):303-9. (PMID: 15907453)
      Eur J Clin Microbiol Infect Dis. 1999 Nov;18(11):761-70. (PMID: 10614949)
      J Chemother. 2019 May;31(3):120-126. (PMID: 30849001)
      Infect Drug Resist. 2020 Jul 14;13:2311-2321. (PMID: 32765007)
      Infect Drug Resist. 2020 Aug 11;13:2773-2781. (PMID: 32848427)
      BMC Infect Dis. 2019 Oct 28;19(1):900. (PMID: 31660862)
      Antimicrob Agents Chemother. 1995 Jan;39(1):185-91. (PMID: 7695304)
      J Glob Antimicrob Resist. 2018 Mar;12:37-43. (PMID: 28893647)
      Antibiotics (Basel). 2022 Mar 21;11(3):. (PMID: 35326884)
      Biomedicine (Taipei). 2018 Mar;8(1):2. (PMID: 29480797)
      Antimicrob Agents Chemother. 2017 Mar 24;61(4):. (PMID: 28115343)
      Microb Pathog. 2023 Apr;177:106051. (PMID: 36858185)
      Can J Infect Dis Med Microbiol. 2020 Feb 24;2020:3826186. (PMID: 32184909)
      Jundishapur J Microbiol. 2016 Jan 02;9(1):e29314. (PMID: 27099689)
      Ethiop J Health Sci. 2021 Jul;31(4):719-724. (PMID: 34703170)
      Braz J Microbiol. 2016 Apr-Jun;47(2):337-44. (PMID: 26991286)
    • Contributed Indexing:
      Keywords: P. aeruginosa; bla OXA−48 gene; MDR; Tn1999; carbapenem resistance; class 1 integron
    • Accession Number:
      EC 3.5.2.6 (beta-Lactamases)
      0 (Carbapenems)
      EC 3.5.2.6 (carbapenemase)
      0 (Bacterial Proteins)
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20241111 Date Completed: 20241112 Latest Revision: 20241116
    • Publication Date:
      20241116
    • Accession Number:
      PMC11556172
    • Accession Number:
      10.1186/s12879-024-10123-7
    • Accession Number:
      39528967